"Global North America Sickle Cell Disease Market Overview:
Global North America Sickle Cell Disease Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global North America Sickle Cell Disease Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of North America Sickle Cell Disease involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the North America Sickle Cell Disease Market:
The North America Sickle Cell Disease Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for North America Sickle Cell Disease Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study North America Sickle Cell Disease Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, North America Sickle Cell Disease market has been segmented into:
Sickle Cell Anemia
Sickle Beta Thalassemia
Sickle Hemoglobin C Disease
By Application, North America Sickle Cell Disease market has been segmented into:
Hydroxyurea
L-glutamine
Crizanlizumab
Pain-relievers
Voxelotor
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The North America Sickle Cell Disease market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the North America Sickle Cell Disease market.
Top Key Players Covered in North America Sickle Cell Disease market are:
Novartis International AG
Bristol-Myers Squibb Company
Global Blood Therapeutics
Inc.
Pfizer Inc.
Emmaus Life Sciences
Inc.
ADDMEDICA
Sangamo Therapeutics
Inc.
Acceleron Pharma
Inc.
Agios Pharmaceuticals
Inc.
Chiesi Farmaceutici S.p.A.
Vertex Pharmaceuticals
Inc.
IMARA
Inc.
bluebird bio
Inc.
CRISPR Therapeutics
Scribe Therapeutics Inc.
Fulcrum Therapeutics
Inc.
HPC International
Editas Medicine
Inc.
Nicox SA
Fera Pharmaceuticals
Tessera Therapeutics
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: North America Sickle Cell Disease Market by Type
4.1 North America Sickle Cell Disease Market Snapshot and Growth Engine
4.2 North America Sickle Cell Disease Market Overview
4.3 Sickle Cell Anemia
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Sickle Cell Anemia: Geographic Segmentation Analysis
4.4 Sickle Beta Thalassemia
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Sickle Beta Thalassemia: Geographic Segmentation Analysis
4.5 Sickle Hemoglobin C Disease
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Sickle Hemoglobin C Disease: Geographic Segmentation Analysis
Chapter 5: North America Sickle Cell Disease Market by Application
5.1 North America Sickle Cell Disease Market Snapshot and Growth Engine
5.2 North America Sickle Cell Disease Market Overview
5.3 Hydroxyurea
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Hydroxyurea: Geographic Segmentation Analysis
5.4 L-glutamine
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 L-glutamine: Geographic Segmentation Analysis
5.5 Crizanlizumab
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Crizanlizumab: Geographic Segmentation Analysis
5.6 Pain-relievers
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Pain-relievers: Geographic Segmentation Analysis
5.7 Voxelotor
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Voxelotor: Geographic Segmentation Analysis
5.8 Others
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 North America Sickle Cell Disease Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 NOVARTIS INTERNATIONAL AG
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 BRISTOL-MYERS SQUIBB COMPANY
6.4 GLOBAL BLOOD THERAPEUTICS
6.5 INC.
6.6 PFIZER INC.
6.7 EMMAUS LIFE SCIENCES
6.8 INC.
6.9 ADDMEDICA
6.10 SANGAMO THERAPEUTICS
6.11 INC.
6.12 ACCELERON PHARMA
6.13 INC.
6.14 AGIOS PHARMACEUTICALS
6.15 INC.
6.16 CHIESI FARMACEUTICI S.P.A.
6.17 VERTEX PHARMACEUTICALS
6.18 INC.
6.19 IMARA
6.20 INC.
6.21 BLUEBIRD BIO
6.22 INC.
6.23 CRISPR THERAPEUTICS
6.24 SCRIBE THERAPEUTICS INC.
6.25 FULCRUM THERAPEUTICS
6.26 INC.
6.27 HPC INTERNATIONAL
6.28 EDITAS MEDICINE
6.29 INC.
6.30 NICOX SA
6.31 FERA PHARMACEUTICALS
6.32 AND TESSERA THERAPEUTICS
Chapter 7: Global North America Sickle Cell Disease Market By Region
7.1 Overview
7.2. North America North America Sickle Cell Disease Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Sickle Cell Anemia
7.2.4.2 Sickle Beta Thalassemia
7.2.4.3 Sickle Hemoglobin C Disease
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Hydroxyurea
7.2.5.2 L-glutamine
7.2.5.3 Crizanlizumab
7.2.5.4 Pain-relievers
7.2.5.5 Voxelotor
7.2.5.6 Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe North America Sickle Cell Disease Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Sickle Cell Anemia
7.3.4.2 Sickle Beta Thalassemia
7.3.4.3 Sickle Hemoglobin C Disease
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Hydroxyurea
7.3.5.2 L-glutamine
7.3.5.3 Crizanlizumab
7.3.5.4 Pain-relievers
7.3.5.5 Voxelotor
7.3.5.6 Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe North America Sickle Cell Disease Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Sickle Cell Anemia
7.4.4.2 Sickle Beta Thalassemia
7.4.4.3 Sickle Hemoglobin C Disease
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Hydroxyurea
7.4.5.2 L-glutamine
7.4.5.3 Crizanlizumab
7.4.5.4 Pain-relievers
7.4.5.5 Voxelotor
7.4.5.6 Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific North America Sickle Cell Disease Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Sickle Cell Anemia
7.5.4.2 Sickle Beta Thalassemia
7.5.4.3 Sickle Hemoglobin C Disease
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Hydroxyurea
7.5.5.2 L-glutamine
7.5.5.3 Crizanlizumab
7.5.5.4 Pain-relievers
7.5.5.5 Voxelotor
7.5.5.6 Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa North America Sickle Cell Disease Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Sickle Cell Anemia
7.6.4.2 Sickle Beta Thalassemia
7.6.4.3 Sickle Hemoglobin C Disease
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Hydroxyurea
7.6.5.2 L-glutamine
7.6.5.3 Crizanlizumab
7.6.5.4 Pain-relievers
7.6.5.5 Voxelotor
7.6.5.6 Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America North America Sickle Cell Disease Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Sickle Cell Anemia
7.7.4.2 Sickle Beta Thalassemia
7.7.4.3 Sickle Hemoglobin C Disease
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Hydroxyurea
7.7.5.2 L-glutamine
7.7.5.3 Crizanlizumab
7.7.5.4 Pain-relievers
7.7.5.5 Voxelotor
7.7.5.6 Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
North America Sickle Cell Disease Scope:
|
Report Data
|
North America Sickle Cell Disease Market
|
|
North America Sickle Cell Disease Market Size in 2025
|
USD XX million
|
|
North America Sickle Cell Disease CAGR 2025 - 2032
|
XX%
|
|
North America Sickle Cell Disease Base Year
|
2024
|
|
North America Sickle Cell Disease Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Novartis International AG, Bristol-Myers Squibb Company, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., IMARA, Inc., bluebird bio, Inc., CRISPR Therapeutics, Scribe Therapeutics Inc., Fulcrum Therapeutics, Inc., HPC International, Editas Medicine, Inc., Nicox SA, Fera Pharmaceuticals, and Tessera Therapeutics.
|
|
Key Segments
|
By Type
Sickle Cell Anemia
Sickle Beta Thalassemia
Sickle Hemoglobin C Disease
By Applications
Hydroxyurea
L-glutamine
Crizanlizumab
Pain-relievers
Voxelotor
Others
|
